CorMedix Inc. Announces the Appointment of Chief Executive Officer
Retrieved on:
Thursday, March 17, 2022
Endo International, Company, Private Securities Litigation Reform Act, Cancer, Business development, Organization, Fast Track, Leadership, Oppenheimer, Marketing, Trial of the century, New chemical entity, Board, Patient, McLennan, Business, CMO, Gabelli School of Business, SEC, Research, Fordham Graduate School of Arts and Sciences, QIDP, Sustainability Accounting Standards Board, Laboratory, CEO, US Market Access Center, Entrepreneurship, Endpoint security, New Drug Application, Oppenheimer Holdings, Georgetown University, Goal, Mark (given name), Nasdaq, MBA, GLOBE, NDA, Marsh McLennan, FDA, File, Pharmaceutical industry, Management, Risk management, Amneal Pharmaceuticals, Ranbaxy Laboratories, Economics, Coronavirus
Myron Kaplan, Chairman of CorMedixs Board of Directors commented, We are delighted to welcome Joe to CorMedix as the new Chief Executive Officer.
Key Points:
- Myron Kaplan, Chairman of CorMedixs Board of Directors commented, We are delighted to welcome Joe to CorMedix as the new Chief Executive Officer.
- CorMedix has a strong late-stage pre-commercial asset in DefenCath with a compelling value proposition for patients in the hemodialysis community, said Mr. Todisco.
- I join my colleagues in welcoming Joe to CorMedix as Chief Executive Officer.
- I look forward to working closely with Joe as we seek to transform CorMedix to a commercial stage entity.